MyFinsight
Home
Blog
About
IMVT_BIG-svg
Immunovant, Inc. (IMVT)
IMVT_BIG-svg
Immunovant, Inc. (IMVT)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from stock options exer...
Stock-based compensation
Other assets
Others
Negative Cash Flow Breakdown
Effect of exchange rate changes ...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-153,224
-147,856
-110,635
-126,502
Stock-based compensation
13,774
11,141
12,715
13,358
Depreciation on property and equipment
92
96
101
105
Non-cash lease expense
27
26
25
24
Accounts receivable
-436
-563
-319
25
Prepaid expenses and other current assets
4,953
-4,313
-2,869
-1,164
Income tax receivable
-
2,386
-
-
Other assets
-6,763
-1,301
38
-167
Accounts payable
2,597
-1,349
1,563
-1,065
Accrued expenses
-
45,000
-
-
Operating lease liabilities
-
-99
-
-
Due to roivant sciences ltd
-
-98
-
-
Accrued expenses and other current liabilities
4,372
-
756
10,259
Net cash used in operating activities
-124,405
-95,059
-92,325
-102,515
Purchases of property and equipment
-
8
0
0
Net cash used in investing activities
-
-8
0
0
Proceeds from issuance of common stock upon underwritten offering, net of underwriter discounts and commissions, and private placement
-
0
544,194
-
Payment of offering and private placement costs
-
-82
586
-
Proceeds from stock options exercised
20,097
3,558
20,995
24,595
Net cash provided by financing activities
20,097
3,640
564,603
24,595
Effect of exchange rate changes on cash and cash equivalents
-4
-988
377
878
Net change in cash and cash equivalents
-104,312
-92,415
472,655
-77,042
Cash and cash equivalents beginning of period
902,110
521,870
521,870
713,971
Cash and cash equivalents end of period
797,798
902,110
994,525
521,870
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from stock
options exercised
$20,097K
(588.73%↑ Y/Y)
Net cash provided by
financing activities
$20,097K
(588.73%↑ Y/Y)
Net change in cash
and cash...
-$104,312K
(9.34%↑ Y/Y)
Canceled cashflow
$20,097K
Stock-based compensation
$13,774K
(-25.59%↓ Y/Y)
Other assets
-$6,763K
(-596.91%↓ Y/Y)
Accrued expenses and
other current...
$4,372K
(182.43%↑ Y/Y)
Accounts payable
$2,597K
(127.62%↑ Y/Y)
Accounts receivable
-$436K
(-237.98%↓ Y/Y)
Depreciation on property and
equipment
$92K
(-14.02%↓ Y/Y)
Non-cash lease expense
$27K
(12.50%↑ Y/Y)
Net cash used in
operating activities
-$124,405K
(-5.96%↓ Y/Y)
Canceled cashflow
$28,061K
Effect of exchange rate
changes on cash and cash...
-$4K
(99.29%↑ Y/Y)
Net loss
-$153,224K
(-27.04%↓ Y/Y)
Buy us a coffee